Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group, double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via immunometabolic geroscience mechanisms.

Brianna. J Stubbs¹, Gabriela Alvarez-Azanedo¹, Sawyer Peralta¹, Stephanie Roa-Diaz¹, Wyatt Gray¹, Laura Alexander¹, Wendie Silverman-Martin¹, Thelma Garcia¹, Traci M. Blonquist², Vaibhav Upadhyay^{3,7}, Peter J. Turnbaugh^{3,4}, James B. Johnson⁵, John C. Newman^{1,6}

¹Buck Institute for Research on Aging, Novato, CA, USA

²Biofortis, Mérieux NutriSciences, Addison, IL, United States,

³ Department of Microbiology & Immunology, UCSF, San Francisco, CA, USA 94143

⁴ Chan Zuckerberg Biohub-San Francisco, San Francisco, CA, USA 94158

⁵ Independent Researcher, Greenbrae, CA, USA.

⁶ Division of Geriatrics, UCSF, San Francisco, California, USA.

⁷ Department of Medicine, UCSF, San Francisco California, USA.

SHORT TITLE: Ketone ester safety and tolerability in older adults

* Correspondence: Dr Brianna J. Stubbs: <u>bstubbs@buckinstitute.org</u>;

Dr John C. Newman jnewman@buckinstitute.org

Study Sponsor Contact: Juniper Pennypacker, VP of Scientific Operations and Chief of Staff, Buck Institute for Research on Aging (jpennypacker@buckinstitute.org) Clinicaltrials.gov registration number: NCT05585762 Current protocol version number and date: version 1.2, approved on 17th January 2023

1 Abbreviations

1-RM	1 Repetition Maximum					
ADL	Activities of Daily Living					
AEs	Adverse Events					
BDO	(R)-1,3-butanediol					
BH-BD	Bis-hexanoyl (R)-1,3-butanediol					
ВНВ	Beta-hydroxybutyrate					
BMI	Body Mass Index					
BO-BD	Bis-octanoyl (R)-1,3-butanediol					
BTQ	Beverage tolerability questionnaire					
CSHA	Canadian Study of Health and Aging					
CRF	Case Report Form					
DSST	Digit Symbol Substitution Test					
IADL	Instrumental Activities of Daily Living					
ITT	Intention to treat					
KEs	Ketone Esters					
MoCA	Montreal Cognitive Assessment					
PLA	Placebo					
РР	Per protocol					
QoL	Quality of Life					
SASP	Senescence-associated secretory phenotype					
SPPB	Short Physical Performance Battery					

4 Abstract

5 **Background:** Frailty is a geriatric syndrome characterized by chronic inflammation and metabolic insufficiency that creates vulnerability to poor outcomes with aging. We 6 hypothesize that geroscience interventions, which target mechanisms of aging, could 7 ameliorate frailty. Metabolites such as ketone bodies are candidate geroscience interventions, 8 having pleiotropic effects on inflammo-metabolic aging mechanisms. Ketone esters (KEs) 9 induce ketosis without dietary changes, but KEs have not been studied in an older adult 10 population. Our long-term goal is to examine if KEs modulate geroscience mechanisms and 11 clinical outcomes relevant to frailty in older adults. 12

Objectives: The primary objective of this randomized, placebo-controlled, double-blinded, parallel-group, pilot trial is to determine tolerability of 12-weeks of KE ingestion in a generalizable population of older adults (\geq 65 years). Secondary outcomes include safety and acute blood ketone kinetics. Exploratory outcomes include physical function, cognitive function, quality of life, aging biomarkers and inflammatory measures.

Methods: Community-dwelling adults who are independent in activities of daily living, with 18 no unstable acute medical conditions (n=30) will be recruited. The study intervention is a KE 19 or a taste, appearance, and calorie matched placebo beverage. Initially, acute 4-hour ketone 20 kinetics after 12.5g or 25g of KE consumption will be assessed. After collection of baseline 21 safety, functional, and biological measurements, subjects will randomly be allocated to 22 consume KE 25g or placebo once daily for 12-weeks. Questionnaires will assess tolerability 23 daily for 2-weeks, and then via phone interview at bi-monthly intervals. Safety assessments 24 will be repeated at week 4. All measures will be repeated at week 12. 25

Conclusion: This study will evaluate feasibility, tolerability, and safety of KE consumption
 in older adults and provide exploratory data across a range of geroscience-related endpoints.

- 28 This data will inform design of larger trials to rigorously test KE effects on geroscience
- 29 mechanisms and clinical outcomes relevant to frailty.
- 30 Words Count: 297 (300 limit)
- 31 Keywords: ketones, ketone ester, ketone di-ester, exogenous ketone, beta-hydroxybutyrate,
- ³² frailty, safety, tolerance, geroscience

34 Introduction

The geroscience approach of modulating fundamental aging mechanisms holds promise 35 for generating new therapeutics for multifactorial conditions of aging which contribute to 36 functional decline, disability, and loss of independence in older adults (1, 2). Frailty syndrome 37 is one such condition, conceptualized as a state of reduced physiological reserve and increased 38 vulnerability to adverse health stresses that is a powerful risk factor for disability, 39 institutionalization, and death (3). Frailty is increasingly common with advancing age, with 40 around 15% of adults over 65 years old in the United States meeting one standard definition 41 (4). The pathophysiology of frailty is complex, multisystem, and poorly understood, but is 42 thought to include cellular energy production deficits along with chronic inflammation and 43 immune dysfunction (5, 6). These are among the molecular mechanisms often referred to as 44 "Hallmarks of Aging", common mechanisms that change with age and underlie many diseases 45 and conditions of aging (7). Geroscience is the emerging field that seeks to manipulate these 46 mechanisms to improve human health. The Geroscience Hypothesis, yet untested in human 47 clinical trials, holds that intervening upon common underlying mechanisms of aging may 48 ameliorate or prevent a variety of both specific chronic diseases of aging as well as 49 multisystem geriatric syndromes such as frailty (1). As of yet, there are no specific molecular 50 therapies for frailty, although exercise programs, specialized geriatric care models, and 51 nutritional interventions can positively alter the frailty phenotype and mitigate its 52 consequences (8). 53

Nutrition and aging have long been intertwined through decades of study of the effects of dietary restriction and fasting on aging in animal models (9) and now humans (e.g. CALERIE (10), HALLO-P (NCT05424042)). A deepening understanding of the molecular mechanisms involved in fasting and dietary restriction has led to small molecule interventions now under investigation in clinical trials targeting various aging phenotypes, as well as a popular upswell

of public and scientific interest in these dietary strategies. One key shared physiological 59 element of such metabolic states is the production and utilization of ketone bodies. Ketone 60 bodies, of which the most abundant is beta-hydroxybutyrate (β HB), are small molecules 61 synthesized in the liver from lipids which circulate in the blood to provide non-glucose energy 62 to extrahepatic tissues such as muscle, brain, heart, and other organs. Ketone bodies are 63 synthesized and circulate constitutively, but are also strongly induced during fasting (11). The 64 energetic and molecular signaling activities of ketone bodies, including supporting 65 mitochondrial function and regulating inflammatory activation, support a mechanistic role in 66 modulating aging and may be directly relevant to frailty (12). We and others previously 67 showed that a ketogenic diet, a dietary method of producing ketone bodies by reducing 68 carbohydrate intake without fasting, extended healthy lifespan in wild-type mice including 69 slowing overall aging-related functional declines, murine clinical frailty scores, and muscle 70 strength declines (13, 14). 71

Ketone esters (KEs), such as bis-octanoyl-(R)1,3-butanediol, are small molecules that 72 deliver ketone bodies without other dietary changes (15, 16). KEs are hydrolyzed in the gut to 73 release ketogenic fatty acids and a ketogenic alcohol, which are then metabolized in the liver 74 to release ketone bodies (17). In preclinical models, ketone bodies and KEs attenuate muscle 75 atrophy through anticatabolic signaling activities (18, 19), improve heart function in age-76 related heart failure through direct energetic support (20, 21), and promote healthy function of 77 T cell subpopulations (22, 23). This hypothesis is further supported by demonstrated effects of 78 KEs on blood glucose control (24-27), physical (28-30), cognitive (31-33), immune (34), and 79 cardiovascular (33, 35) function in younger adult populations. These examples support our 80 central hypothesis that ketone bodies delivered through KEs may ameliorate the frailty 81 syndrome through multi-system energetic and signaling activities that improve metabolic and 82 immune function. KEs have not been investigated in older adult populations. 83

Here we describe the protocol for a randomized, placebo-controlled, double-blinded, 84 parallel-group pilot clinical trial with the objective of generating the first human safety and 85 tolerance data for KEs in a generalizable population of older adults: The Buck Institute Ketone 86 Ester (BIKE) Study. The placebo for BIKE contains canola oil, an inert, non-ketogenic fat, 87 commonly found in the food supply. BIKE is designed as an example of a proof-of-concept 88 geroscience clinical trial (2): specifically assessing an intervention for tolerability and safety 89 in a broad population of older adults, targeting specific aging-related molecular mechanisms, 90 and linking those mechanisms to a clinically important outcome that is broadly representative 91 of aging. We will collect exploratory data on clinical outcomes related to frailty and biological 92 aging mechanisms, which will facilitate future planned work on clinical outcomes of KE 93 consumption in a pre-frail or frail population. 94

95 Methods

% Study Design Overview

The Buck Institute Ketone Ester (BIKE) Study is a randomized, double-blind, placebo-97 controlled, parallel group, pilot study designed to assess the feasibility, safety, and tolerability 98 of up to 25 g/day of KE ingestion for 12 weeks compared to a placebo in older adults (≥ 65 99 years of age), and to generate exploratory data on endpoints related to aging and frailty 100 (Figure 1 and 2). Following Consent and Screening (Visit 1), Acute Ketone Kinetics are 101 measured during Visit 2, *Baseline* measures are collected at Visit 3 (week 0), daily KE or 102 placebo consumption begins (day 1), an Interim Safety assessment is performed at Visit 4 103 (week 4), and *Final* post-intervention measures are collected at Visit 5 (week 12). Tolerance is 104 assessed during phone calls every 2 weeks. The study protocol described here has been 105 approved by Advarra Institutional Review Board (current version 1.2 approved on 17th 106 January 2023), any further ammendments will be reported to the sponsor and approved by the 107 IRB. The study is registered with clincaltrials.gov (NCT05585762), all items from the WHO 108 Trial Registration Dataset are included in Supplementary Table 1. Recruitment for the study 109 began on November 28th 2023. Here we present details of the study protocol according to 110 SPIRIT 2013 guidelines (36) (SPIRIT checklist provided in Supplemental File) 111

112 [FIGURE 1 HERE]

113 Figure : Schedule of BIKE Study screening, interventions and assessments- SPIRIT Figure

114 [FIGURE 2 HERE]

115 *Figure 2: BIKE Study design schematic.*

116 Study Setting

The BIKE Study is conducted by investigators and clinical research staff at The Buck Institute for Research on Aging, an academic institutions based in Northern California, USA. Study procedures are conducted in the Clinical Research Unit at The Buck Institute. The majority of
subjects are expected to be residents of Northern California.

121 Study Population

Subjects (n = 30) in the BIKE Study are community dwelling older adults (\geq 65 years) in stable health, with roughly equal distribution of male and female subjects. Equal enrollment of males and females is important, as frailty is more common in women yet mortality is higher in men, and detailed pathophysiology may differ between sexes (37).

Inclusion criteria are broad, and exclusion criteria relatively limited, in order to enroll a generalizable sample of older adults. Many subjects will have common chronic diseases and be taking multiple medications. Stable chronic disease and medications are not an exlcusion, except for specific items that may interact poorly with anticipated KE side effects such as gastrointestinal upset. Inclusion and exclusion criteria are found in Table 1:

131 **Table 1:** Inclusion/Exclusion Criteria

Inclusion Criteria

- Men and women age ≥ 65 years
- BMI 18.5-34.9 kg/m² (inclusive at Screening/Consent Visit)
- No health conditions that would prevent them from fulfilling the study requirements as judged by the Clinical Investigator based on medical history and routine laboratory test results

Exclusion Criteria

- Non ambulatory
- Canadian Study of Health and Aging (CSHA) clinical frailty score > 5
- Required assistance with any activity of daily living except continence
- Living in an institutional setting

- Hospitalization within 30 days of the Screening/Consent Visit
- Abnormal laboratory test result(s) of clinical importance, indicating unstable chronic disease of major organ dysfunction (at the Screening/Consent Visit), at the discretion of the Clinical Investigator
- History or presence of uncontrolled and/or clinically active pulmonary, cardiac (e.g., >= New York Heart Association class III), hepatic, renal, endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and/or anxiety disorders) or biliary disorders. Stable chronic disease is not an exclusion criterion unless specified
- History or presence of a clinically important gastrointestinal condition that could potentially interfere with the evaluation of the study beverage, at the discretion of the Clinical Investigator, including inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation, frequent diarrhea, surgery for weight loss, gastroparesis, systemic disease that might affect gut motility, reflux requiring daily medication, gastrointestinal ulcers or bleeding and clinically important lactose intolerance
- Uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as measured at the Screening/Consent Visit. One re-test will be allowed on a separate day prior to Visit 2
- Use of medications (over-the-counter or prescription) known to influence gastrointestinal function including, but not limited to, opioids, anti-diarrheal, and anti-spasmodic) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Unstable use of thyroid, antihypertensive, antidepressant, or statin medications

within 6 months of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits

- Undergoing treatment or active surveillance for cancer, or has been diagnosed with cancer in the prior two years (except for non-melanoma skin cancer)
- Recently used antibiotics within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Presence of a condition that would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk, at the discretion of the Clinical Investigator
- History of alcohol or substance abuse
- Consistent use of prescriptive or over-the-counter medications where alcohol is a contraindication, at the discretion of the Clinical Investigator
- Known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages, including soy and milk protein
- Extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Use of weight-loss medications (including over-the-counter medications and/or supplements) or programs within 30 days of the Screening/Enrollment, Acute Ketone Kinetics, or Baseline Visits
- Use of ketone supplements (ketone salts or esters, and medium chain triglyceride oils) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Working at night or shifts that will impede maintaining a consistent meal schedule

during the study

- Inability to confirm COVID-19 vaccination status
- (For female subjects) not have passed menopause, is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period

132 Study Intervention and Placebo

The BIKE Study KE beverage is a tropical-flavored beverage containing the KE bis-octanoyl 133 (R)-1,3-butanediol (BO-BD) (BHB Therapeutics Ltd, Dublin, IRE). Each bottle is 75 mL and 134 contains 25 g of KE. This KE was developed to resolve palatability issues with the first KE 135 beverage launched by BHB Therapeutics (bis-hexanoyl (R)-1,3-butanediol, BH-BD). Both 136 BO-BD and BH-BD are expected to be metabolized similarly, and deliver a rapid increase in 137 circulating ketone concentrations (15, 16, 38, 39). Subjects will consume the study beverage 138 daily for 12 weeks at home within 5 minutes of breakfast. Half of a bottle (12.5 g KE) is 139 consumed daily during week 1, and a full bottle daily (25 g KE) for the remainder of the 140 study; this acclimation period is designed to reduce gastrointestinal issues and we have used it 141 sucessfully in our studies of younger adults (40). No modifications to this schedule are 142 permitted, participants may discontinue at their request or at the discretion of the study 143 medical officer. The placebo used in the study was custom manufactured by BHB 144 Therapeutics. It is matched for volume, appearance, flavor, and calories; the KE is replaced by 145 non-ketogenic canola oil. Subjects will be contacted by the study team every 2 weeks to 146 review their study product use, which is expected to improve adherance and retention. 147 Compliance will be assessed by daily completion of a paper Study Beverage Log reported by 148 study subjects. The log will be compared to the number of unopened bottles returned at week 149

4 and week 12 visits. Subjects who consume between 80 – 120% of their allocated study
product will be considered 'per protocol.'

152 Study Outcomes

Primary outcome: The primary outcome of the BIKE Study is tolerability of the KE 153 intervention, assessed using a beverage tolerability questionnaire (BTQ) (41, 42). The BTQ 154includes ten symptoms: gas/flatulence, nausea, vomiting, abdominal cramping, stomach 155 rumbling, burping, reflux (heartburn), diarrhea, headache, and dizziness. Subjecs are either 156 asked if the issue occurred since they took the study beverage (paper questionnaire completed 157 daily 3-6 h after KE consumption during 2-week acclimation period) or during the last week 158 (completed verbally during bi-weekly telephone call), and asked to rank the intensity as none, 159 mild, moderate or severe. These correspond to scores of 0-3 respectively for each issue, giving 160 a maximal composite score of 30. After acclimation, subjects are asked to report the number 161 of days that each symptom occurred. 162

The key tolerability outcome is the proportion of subjects reporting the same moderate to severe symptom (among dizziness, headache, or nausea) occurring on more than one day within any given two week recall period (after week 0–2 acclimation period).

Headache, nausea, and dizziness were selected as they occurred significantly more often at 166 mild severity in our previous 28-day study of a KE in healthy adults (40). The 'moderate to 167 severe' intensity was selected as 'mild' symptoms are common in this population (43), and 168 may be acceptable if they are outweighed by benefits of the intervention. Moderate to severe 169 symptoms are less common (44) and more likely to be deterimental to quality of life or 170 function. The frequency of 'more than one day per period' is used to reduce the impact of 171 idiosyncratic symptoms on the analysis given the common occurance of such symptoms in the 172 target population. 173

Secondary outcomes: Safety is a secondary outcome of the BIKE Study; assessed through 174 changes over time in clinical and laboratory measures throughout the study within each group. 175 Laboratory tests run at screening and blood samples at Baseline, Interim Safety and Final 176 *Visits* (weeks 0, 4, and 12) include hematology, chemistries, liver function tests, and thyroid 177 function tests. Based on previous data on KE effects, we are particularly focused on potassium 178 (45, 46) and bicarbonate (46, 47) along with liver function tests as KEs exploit natural hepatic 179 metabolism in generating ketone bodies. Changes in body weight, heart rate, systolic and 180 diastolic blood pressure, and orthostatic changes in blood pressure will be followed at the last 181 three study visits. KEs may increase resting heart rate (45, 48) and increase blood flow to the 182 brain and heart via vasodilation (45, 48, 49) which, while potentially therapeutic, require 183 monitoring. KEs are not associated with weight loss (40, 50, 51), but body weight is followed 184 to ensure that gastrointestinal side effects or taste do not cause clinically meaningful weight 185 loss. The key safety outcome is the longitudinal within-group change in safety blood 186 parameters. Our previous 28-day study of healthy adults did not find any clinically meaningful 187 changes in labs (40), nor were any present in other studies of KEs (50, 51). However, our 188 target population will likely include a greater proportion of potentially interacting 189 comorbidities and medications compared to these prior studies. 190

A further secondary outcome is monitoring the acute changes in blood ketone and glucose 191 conentrations for 4 h post-consumption of a serving of KE, which has not be studied in an 192 exclusively older adult cohort. At the Acute Ketone Kinetics Visit (Visit 2), subjects will be 193 randomly allocated to consume either 12.5g or 25 g of KE after a standard breakfast. Prior to 194 KE ingestion, and at regular intervals for 4 h following, capillary blood samples will be 195 obtained from a finger and analysed instantly for BHB and glucose concentrations using a 196 handheld device (Keto Mojo, CA, USA). We will compare the changes over the Acute Ketone 197 Kinetics study day both from t = 0 and between the serving size groups. A subset of subjects 198

will wear a continous ketone monitor (Abbott, IL, USA) for the first two weeks of the study,
to provide data confirming the repeatability of BHB kinetics at home.

Exploratory outcomes: Exploratory outcomes include longditudinal changes in physical and cognitive function, quality of life (QoL), and geroscience biomarkers in the KE and placebo groups. These are assessed at *Baseline* (Visit 3, week 0) and *Final*, post-intervention (Visit 5, week 12) timepoints unless otherwise stated; notably no study beverage is consumed on the morning of any study visits .

Exploratory physical function measures will be collected at week 0 and 12 as follows: 1 206 repetition maximum (1-RM) leg press strength, 70% 1-RM leg press fatiguability, 4 m gait 207 speed, Short Physical Performance Battery (SPPB), 4 m gait speed is a component of SPPB 208 but analyzed independently as well) (52), 6-minute walk test (53), grip strength via 209 dynamometer, and actigraphy via FitBit. A recent consensus statement from the International 210 Conference on Frailty and Sarcopenia Research Task Force on designing drug trials in frailty 211 recommends these measures (54). Similar outcomes were used in the CRATUS trial of 212 mesenchymal stem cells (55), ENRGISE trial of losartan and fish oil (56), LIFE physical 213 activity trial (57), and a senolytic clinical trial (58), and are proposed for TAME (59). The 214 selected measures have strong predictive value for disability (8, 60, 61). Physical performance 215 216 is also likely to be more dynamic in a 12-week study than longer-term clinical measures such as chronic diseases or disability. 217

The exploratory cognitive measures assessed at week 0 and 12 include a standard cognitive screen (Montreal Cognitive Assessment or MoCA) (62), as well as quantitative measures of processing speed which are more likely to improve with the intervention within 12 weeks. (Trails A, Trails B (63), and the Digit-Symbol Substitution Test or DSST (64)). MoCA and Trails A/B are components of the National Alzheimer's Coordinating Center Uniform Data Set Version 3 (65).

Other exploratory geriatric outcome measured at week 0 and 12 include Activities of Daily 224 Living (ADLs), Instrumental Activities of Daily Living (IADLs), Fried Frailty Index, and 225 CSHA Clinical Frailty Score, which are crucial assessments of overall health although 226 unlikely to change in 12 weeks (66). Quality of life measures were chosen based on relevance 227 to frailty and factors that have been anecdotally reported to change with KE use. QoL will be 228 assessed using: SF-36 (67), Profile of Mood States - Short Form (68), Sexual QoL 229 Questionnaire (Male or Female version), Pittsburgh Sleep Quality Index (69), Pittsburgh 230 Fatiguability Scale (70), and Geriatric Depression Scale (71). 231

Biomarkers in geroscience interventional clinical trials may include those related to the 232 pharmacokinetics or downstream mechanisms of the intervention, and biomarkers (2) to help 233 test if the intervention broadly impacts aging as per the Geroscience Hypothesis (72). We will 234 test exploratory biomarkers at week 0 and week 12 including: 1) blood tests identified by the 235 TAME Biomarkers Workgroup as potentially useful in an interventional trial (72), 2) 236 composite biomarkers using routine laboratory tests, 3) comprehensive 69-mer cytokine panel 237 (via the TGN Facility for Geroscience Analysis), 4) DNA methylation for use in aging clock 238 models and 5) alterations in gut microbiome using stool sample analysis at intervals through 239 the study. 240

The TAME Biomarkers Workgroup formulated criteria for biomarkers in geroscience clinical 241 trials that include feasibility and reliability, biological plausibility, robust association with 242 risk, and responsiveness to interventions (72). This resulted in a list of 9 biomarkers: IL-6, 243 CRP, sTNFR1, Cystatin C, IGF-1, NT-proBNP, insulin, GDF15, and IGFBPs. IL-6, CRP, 244 and sTNFR1 are implicated in frailty (73-75), and along with insulin, IGF-1, and IGFBPs, 245 may be directly or indirectly regulated by ketone bodies. The comprehensive 69-mer cytokine 246 panel is optimized for immunosenescence and SASP and includes TNF α , IFN γ , IL-6, IL-8, 247 IL-10, IL-17, IL1 β , sTNFR1/2, and more. We will apply three composite aging biomarkers 248

derived from routine laboratory tests: Belsky, FI-LAB and DNA methylation. Belsky et al.

developed two biomarkers based on the Klemera-Doubal Method and a homeostatic

dysregulation model and showed that the dietary restriction intervention in CALERIE slowed

both measures (76). FI-LAB is a clinical frailty index derived from 21 common laboratory

tests plus blood pressure that predicts mortality among older adults (77, 78). We will isolate

²⁵⁴ peripheral blood mononuclear cells for DNA methylation analysis which will allow

application of aging 'clocks.'

The effect of KE on the human microbiome is not yet known. Ketogenic diet rapidly alters the microbiome in both humans and mice, and in mice both KD and KE can reduce systemic proinflammatory Th17 cells and alter the gut microbiota (22). To address this we will collect five stool specimens from each subject (before Visit 2, before Visit 3, one week post-Visit 3, immediately post- week 4, at week 12) to identify acute and chronic (across the 20 weeks) changes in the microbiome.

262 Subject Timeline

For all in-person visits, subjects must meet the following pre-test criteria: fasting $\geq 10h$, no alcohol $\geq 10h$, no exercise $\geq 10h$, no pyschoactive cannabis products $\geq 10h$. They will be queried on arrival to confirm compliance. At every visit, subjects will be queried on their use of any new medications and supplement, or any changes to their health. Subjects will also be queried to ensure compliance with study protocol, and will be reminded of study instructions. A summary of procedures is shown in **Figure 1**.

Telephone screening: Subjects will complete a telephone screening to assess initial eligibility
by confirming their age, that they are independent on elements of activities of daily living
(ADL), any allergies, and the absence of recent hospitalizations.

Screening Visit (Visit 1): Subjects will provide written informed consent after discussing the study procedures with a registered nurse and prior to collection of blood and urine samples, demographic information, medical history, ADL, IADL and CSHA frailty scoring, and measurement of vital signs by a registered nurse. These data will be reviewed by an independent study medical officer who will make final decisions on eligibility and enrollment into the study. Subjects will be asked to taste the study beverage and confirm that they are willing to consume it daily for 12-weeks. Subjects will receive a stool sample kit for at-home collection prior to Visit 2.

Acute Ketone Kinetics Visit (Visit 2): Subjects will be randomly allocated to either 12.5g or 280 25 g of KE following a standard breakfast (oatmeal with protein powder). Before and 4 h after 281 study beverage consumption, subjects will verbally complete the BTQ described above, to 282 determine the incidence of any side-effects during the visit. Capillary blood samples will be 283 obtained by a research associate from a finger using a lancing device, and analyzed instantly 284 and glucose concentrations using a handheld device (KetoMojo, CA, USA). 285 for BHB Collection time points are: pre-consumption, 30-, 60-, 90-, 120-, 180- and 240-minutes post-286 consumption. Study staff are not blinded to serving size for this visit. Subjects will be 287 familiarized with the physical function tests that will be completed at Visit 3, and receive 288 instruction on how to capture one day's food intake with an online diet log (ASA-24, 289 NCI(79)) and be given a FitBit Inspire 2 device (FitBit, CA, USA) to wear for the remainder 290 of the study in addition to a second stool sample kit for at-home collection prior to Visit 3. 291

Baseline Visit (Visit 3, week 0): Fasted blood and urine samples will be collected for analysis as described above. Vital signs will be assessed after subjects have completed QoL questionnaires. Physical and cognitive function will be tested as described above; tests will be performed by a trained and certified (where appropriate) registered nurses or research associates. A continuous ketone monitor will be applied to a subset of subjects. Subjects will be given the Study Beverage Log that will be completed each day at home, a stool sample kit for at-home collection one week after Visit 3, and a one-month supply of their study beverage,
plus overage (35 bottles).

At-home procedures: Subjects will consume the study beverage every day for 12-weeks 300 within 5 minutes after their breakfast. For the first week, they will consume half of a bottle 301 daily (12.5 g KE), and for the remainder of the study they will consume a full bottle daily (25 302 g KE). They will complete a Study Beverage Log to indicate time of product consumption. 303 Additionally, for the first two weeks (acclimation period), a full BTQ will be completed each 304 day. For the remainder of the study, an open-ended question will allow subjects to record any 305 side effects that they experience each day. The Study Log will be reviewed for compliance 306 and BTQ outcomes during bi-weekly phone calls (week 2, 6, 8 and 10) and at Visit 4 and Visit 307 5. Adverse events (AEs) will also be queried during each phone call. The final month's supply 308 of product will be mailed to subjects during week 7, along with a stool sample kit for at home 309 collection up to 3 days before Visit 5. 310

Interim Safety Visit (Visit 4, week 4): Tolerability will be assessed by verbal completion of 311 the BTQ, and AEs will be queried. Fasted blood and urine samples will be collected for safety 312 lab analysis. Adherence will be monitored by review of the Study Beverage Log and counting 313 of unused bottles of product brought in by the subject. One months' supply of product plus 314 overage (35 bottles) will be provided for subjects to take home, along with a new Study 315 Beverage Log. Subjects will be given a stool sample kit for at home collection 3 days after 316 Visit 4. The independent study medical officer will review the safety lab results to approve 317 continuation of subjects in the study. 318

319 Final Visit (Visit 5, week 12):

The Final Visit is identical to the Baseline Visit, except that the following will not take place: application of continuous ketone monitor, provision of study beverage, and Study Beverage Log distribution. The following will take place: collection of Study Beverage Log, compliance monitoring, verbal BTQ administration, and AEs query.

324 Sample size

Based on studies of symptoms in older adults (43, 44), we predict the primary outcome rate in the placebo group will be approximately 10%. N = 30 (15 per arm) provides 36% power to detect a 25% increase (from 10% to 35%) in the proportion of subjects meeting this primary outcome in the KE condition with two-sided α =0.10. If we assume a larger effect of the KE intervention, n = 30 (15 per arm) provides approximately 75% power to detect an increase (from 10% to 55%) in the proportion of subjects meeting this primary outcome in the KE condition, with two-sided α =0.10.

332 **Recruitment**

Initial recruitment is via sharing of study information on the Buck Institute website, outreach to a voluntary mailing list of interested individuals maintained by the Buck Institute, and via response to public outreach including a local newspaper article and talks at community group events. Further recruitment plans include ongoing engagement with community groups serving older adults, outreach to organzations representing communities underrepresented in medicine, and flyer mailings targeted to communities underrepresented in medicine.

339 Allocation and Blinding

Study beverage sequence allocation will occur randomly, based on a block allocation sequence prepared by a statistician. It will result in a 1:1:1:1 breakdown of subjects to receive either 12.5 or 25 g of KE at the *Acute Ketone Kinetics* Visit, and then either KE or placebo beverage for the 12-week study. Stratification by sex will occur to ensure equal allocation to each group. Allocation will occur at Visit 2, with the sequence assigned by the research team in the order of subject enrollment.

Study beverage will be coded and labelled by external personnel and all study staff will 346 remain blinded to the code allocation of the beverage throughout the study, but not the group 347 allocation of the subject. Unblinding will occur after compeletion of all subjects and after 348 analysis of the primary data outcome by an external statistician. Written procedures govern 349 emergency unblinding of individuals or the study as a whole. Individual subjects are provided 350 with a pocket card including their allocation code and a description of anticipated possible 351 clinical effects of KE. They will have their allocation revealed to them and their health care 352 providers via the study medical officers (in consultation with the principal investigator) if it is 353 determined that unblinding is necessary for the care of an adverse event. In such an instance, 354 allocation coding will remain blinded to the principal investigator, study staff, and all other 355 subjects. 356

357 Subject Retention

Retention will be facilitated by building rapport with subjects during early study visits and ongoing bi-weekly contact with study subjects via telephone calls as well as email reminders of upcoming visits. In addition, stipends will be paid at the end of each visit; the value of the stipend increases each visit to incentivize continued participation.

362 Data Management and Dissemination

Data will be entered into paper case report forms (CRFs) during study visits by research 363 associates or registered nurses and reviewed for completeness by an investigator before it is 364 transcribed into an electronic datasheet. Every effort will be made to maintain subject 365 confidenitality before, during, and after the study. CRFs and entries into the electronic data 366 sheet are idenitifed by subject number, and the code-break linking the subjects' name to their 367 study number is stored seperately to the CRFs. CRFs are kept in secure cabinet in a room with 368 limited access. The electronic datasheet is stored on a secure internal server at The Buck 369 Institute. Data will be spot-checked for quality during the study closure, and retained for up to 370

371 5 years after closure.

Research data will be shared according to the most recent NIH guidelines. We are committed 372 to the sharing of final research data, being mindful that the rights and privacy of people who 373 participate in research must be protected at all times and that there is the need to protect 374 patentable and other proprietary data. Any datasets will be free of any identifiers that would 375 permit linkages to individual research participants and variables that could lead to deductive 376 disclosure of individual subjects. Anonymized raw, subject-level data will be held at The Buck 377 Institute under the custody of the Principal Investigator and de-identified data will be made 378 available upon reasonable written request to the PI. The results of the study will be 379 disseminatied via publication in scientific papers, abstracts, and presentations. Authorship will 380 be determined by ICMJE guidelines, manuscripts will be prepared by the study team. 381

382 Statistical Analysis

All analyses will be based on intention to treat and will be conducted by an external study 383 statistician who will be blinded to intervention coding. The proportion of subjects with the 384 primary outcome will be compared between groups with Fisher's exact test. The frequency of 385 each individual symptom and the frequency of mild symptoms will be explored with 386 categorical data analysis methods. The total composite scores will be evaluated with a 387 Wilcoxon rank sum test. During the 14-day acclimation period, the daily composite score will 388 be calculated as the sum of the individual items and will be analyzed with a random 389 coefficient model. The within-group change in safety labs will be compared between groups 390 with a Wilcoxon rank sum test and a false discovery rate adjustment to control for multiple 391 comparisons. Changes in continuous secondary and exploratory outcomes will be compared 392 between groups with an analysis of covariance approach or a repeated measures model. The 393 intent-to-treat (ITT) population will comprise data for all subjects who were randomized and 394 consumed one serving of the study beverage. In addition, the per protocol (PP) population 395

will be identified as a subset of the ITT population, in which subjects will be excluded for the 396 following reasons and possibly others: violations of inclusion or exclusion criteria that could 397 influence the evaluation of response, non-compliance by the subject, including, but not 398 limited to: use of prohibited drugs or any products thought to alter the primary outcome 399 variable during the study, less than 80% or more than 120% compliance with study beverage 400 consumption, or not adhering to instructions as outlined in the protocol. All decisions 401 402 regarding exclusion from the ITT and PP populations will be documented prior to database lock. Missing data will not be imputed. 403

404 Safety Monitoring and Oversight

Remote and on-site monitoring visits will be conducted periodically during the study, focusing on human subject protection and data integrity risks of the trial. A clinical monitoring plan will be developed which identifies specific risk-based monitoring focal points. These may include:, informed consent, eligibility criteria, adverse events, protocol deviations, endpoints, study beverage accountability.

Independent study medical officers will be retained tomonitor the study data, they will be practicing physicians with experise in geriatric medicine. The medical officers will make final determinations on all study enrollment, continuation (*Interim Safety Visit*), and discontinuation decisions, as well as review any serious adverse events and events of note, and consult with the study team on any other adverse events. The Buck Institute designated an institutional officer to represent the Institute and the philanthropic funders .

Adverse events will be queried at visits and telephone calls and recorded in the CRF. Serious adverse events will be reported to the medical officers, institutional officer, and the IRB. 'Events of note' are a subset of adverse events that result in discontinuation from the study, require treatment or require diagnostic evaluation. No interim analysis is planned, however if a pre-determined threshold of excess events of note occuring in one of the study groups is reached, or if a serious adverse event occurs the committee comprising of the medical officers,
institutional officers, and principal investigator will convene to discuss unblinding and study
pausing or discontinuation. No medical care will be provded during the study and no form of
compensation is offered for any injury.

This pilot study will provide important new information on the application of ketone 426 body biology to human health and disease in aging. Firstly, KEs have not been rigorously 427 tested in older adults, therefore the data resulting from this study will support further research 428 with KEs in other age-related conditions. Secondly, the particular KE under investigation here 429 is more palatable than existing products, and as it requires endogenous production of ketone 430 bodies from the fatty acid components it more closely mimics dietary ketosis. Thirdly, this 431 will be the most direct test to date of KE effects on geroscience pathways in humans, 432 beginning to extend into humans the extensive pre-clinical literature linking ketosis to aging 433 mechanisms. Fourthly, as ketone bodies are generated endogenously during both caloric 434 restriction and exercise, KE can provide more specific mechanistic insight into the clinical 435 effects of such interventions as in the NIH-funded CALERIE and HALLO-P trials. Finally, 436 this is intended to be an example of an early proof-of-concept clinical trial testing the 437 biological effects of a geroscience-guided intervention, with many elements of its design 438 based on frameworks developed by the NIH-funded Translational Geroscience Network (2). 439 These design and conceptual elements include the goal of specifically assessing safety in an 440 older population, focusing on a broadly representative and generalizable population, the use of 441 functional outcome measures, and the combination of intervention-specific with general aging 442 biomarkers. Translational geroscience is an emerging field, and early-stage clinical trials have 443 been identified as the key bottleneck in the development of interventions, as well as being 444 critical for training the next generation of investigators (80). 445

The need to carefully balance safety in a less resilient population with the desire to generate meaningful data in our exploratory outcomes led to the selection of the 12-week study duration. Studies of KEs in younger adults have demonstrated safety over a 28-day study period, hence 12-weeks represents a significant extension of the existing data. The

Interim Safety Visit (Visit 4, week 4) is designed to ensure that subjects do not continue in the study if clinically meaningful negative changes to blood safety labs occur. Assuming positive safety and tolerability findings in this population, the study duration could be extended in future work.

Similarly, serving size selection for this study took into consideration multiple factors 454 including feasibility, safety, and likely efficacy. Some functional endpoints, such as cognition 455 (81) and cardiac function (45), appear to be responsive to the blood concentration of BHB, 456 hence giving the maximal tolerable KE serving size could increase the chance of observing 457 KE efficacy. Whilst some KEs have been studied at serving sizes up to 75 g/day for 28 days, 458 the KE family used in this study has only been studied up to 25 g/day for 28 days, hence why 459 the 25 g serving size was selected for this first-in-older-adults 12-week study. Splitting the 460 daily serving into multiple smaller boluses through the day may have provided greater total 461 time in nutritional ketosis for each study day, however there is no definitive evidence to 462 support increased time in ketosis vs. a higher BHB peak. Increasing the subject burden and 463 thus increasing the chance of non-adherence or drop-outs by requiring twice daily 464 consumption was identified as a more important consideration than consistent ketosis 465 coverage, hence why 25 g/day servings in one bolus was chosen. If safety data for this KE 466 were expanded, larger serving sizes could be implemented in future work. 467

Study population selection was another area of careful consideration. Whilst the study is intended to recruit healthy individuals, older adults unavoidably have a greater incidence of concurrent health conditions and medication use. Requiring no medication use and no active conditions would be prohibitive for recruitment in an older adult population, and would both exclude the pathophysiology of interest while sharply limiting relevance and generalizability to the majority of older adults. With this in mind, we set intentionally broad inclusion and exclusion criteria; as subjects must be independent for all activities of daily living (excluding

self-managed continence issues) and we explicitly exclude a range of relevant active and unstable conditions, this will exclude most actively unwell individuals. The aim is to include healthy older adults, accepting that this includes individuals who are managing some health conditions.

The field of geroscience translational clinical trials is relatively new and 479 standardization of outcome measures across studies presents both challenges and opportunities 480 (2). The outcome measures included in this study were chosen based on their hypothesized 481 sensitivity to our KE intervention and to harmonize between other innovative geroscience 482 clinical trials, the latter representing a major strength of this protocol. The ability to compare 483 between study populations will inform the clinical significance of any changes following the 484 KE intervention compared with other proposed geroscience interventions. Although some of 485 the exploratory outcome measures are unlikely to change over the study period in a healthy 486 population (i.e., ADL, IADL, SPBB, MoCA), others may be more dynamic (i.e., blood 487 biomarkers, grip strength, 1-RM). Future work in a frail or pre-frail population, with a longer 488 study period and increased KE serving size, would increase the probability of detecting 489 significant changes in these measures. 490

491 Sources of Funding, Author Declarations and Conflict Management:

Funding for BIKE is provided by philanthropic donations from Dr James B. Johnson and from members of the Buck Institute Impact Circle. Dr Johnson assisted with conceptualization of the study and reviewed this manuscript but has no further role in study design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications. The Buck Institute Impact Circle has no role in conceptualization, study design, management, data collection, analysis, interpretation of data, decision to submit publications, review, or writing of publications.

Dr Newman's participation in the study is supported by Buck Institute institutional funds. Dr
Brianna Stubbs' participation in the study is supported by supported by the NIH (NIA) under
award number K01AG078125.

The KE intervention is provided gratis by BHB Therapeutics Ltd (Ireland). BHB Therapeutics also arranged for manufacture of the matched placebo, paid from BIKE study funds. BHB Therapeutics markets formulated KE beverages to consumers. BHB Therapeutics provided no funding for the study, and has no role in the design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications.

508 The principal investigator (Dr. Newman), Dr. Brianna Stubbs, and the Buck Institute hold shares in BHB Therapeutics. Drs. Newman and Stubbs are inventors on patents relating to the 509 use of ketone bodies that are assigned to The Buck Institute. All other authors have no 510 conflicts to declare. Individual and institutional extensive conflict management plans were 511 developed and approved by the Buck Institute and the IRB. Actions and decisions important 512 to subject safety and study integrity are carried out by parties with no potential financial 513 conflict. Participant consent is obtained by licensed registered nurses who have no financial 514 conflict. Decisions on subject enrollment, continuation, and discontinuation are made by 515

independent medical officers unaffiliated with Buck Institute and with no financial conflict.
Data analysis for the primary outcome is carried out by an independent statistician with no
financial conflict. Study staff, including the principal investigator, will maintain blinding
through study completion unless unblinding is required for safety concerns.

520 Author Contributions: Conceptualization, J.C.N, J.B.J, B.J.S.; methodology, all; writing-

original draft preparation, G.A.A, B.J.S; writing—review and editing all; visualization, B.J.S,

J.C.N; project administration, B.J.S, J.C.N, T.G; supervision: B.J.B, T.G, J.C.N; funding

⁵²³ acquisition, B.J.S, J.C.N; All authors have read and agreed to the published version of the ⁵²⁴ manuscript.

Institutional Review Board Statement: This study will be conducted according to the guidelines of the Declaration of Helsinki (2004), and the first version of the study documents were approved by Advara IRB on September 28, 2022 (current version was approved 17th January 2023).

529	Reference List
530	
531	1. Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, et al.
532	Strategies and Challenges in Clinical Trials Targeting Human Aging. J Gerontol A Biol Sci
	Med Sci. 2016;71(11):1424-34.
533	With Sci. 2010,71(11).1424-34.
534	2. Justice J, Miller JD, Newman JC, Hashmi SK, Halter J, Austad SN, et al. Frameworks
535	for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging
536	Processes. J Gerontol A Biol Sci Med Sci. 2016;71(11):1415-23.
537	3. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management
538	of frailty: opportunities, challenges, and future directions. Lancet. 2019;394(10206):1376-86.
539	4. Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al.
540	Frailty in Older Adults: A Nationally Representative Profile in the United States. J Gerontol
	A Biol Sci Med Sci. 2015;70(11):1427-34.
541	A DIOI SCI MEU SCI. 2013,70(11).1427-54.
542	5. Zampino M, Brennan NA, Kuo PL, Spencer RG, Fishbein KW, Simonsick EM, et al.
543	Poor mitochondrial health and systemic inflammation? Test of a classic hypothesis in the
544	Baltimore Longitudinal Study of Aging. Geroscience. 2020;42(4):1175-82.
	C Emeral I. Eshhai E. Inflamma in a sharri inflamma (in in a single and in a s
545	6. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular
546	disease, and frailty. Nature reviews Cardiology. 2018;15(9):505-22.
547	7. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging:
548	An expanding universe. Cell. 2023;186(2):243-78.
010	
549	8. Walston J, Buta B, Xue QL. Frailty Screening and Interventions: Considerations for
550	Clinical Practice. Clin Geriatr Med. 2018;34(1):25-38.
551	9. Green CL, Lamming DW, Fontana L. Molecular mechanisms of dietary restriction
552	promoting health and longevity. Nat Rev Mol Cell Biol. 2022;23(1):56-73.
552	promoting neurin and iongevity. Nat Nev Wol Cen Diol. 2022,25(1).50-75.
553	10. Rickman AD, Williamson DA, Martin CK, Gilhooly CH, Stein RI, Bales CW, et al.
554	The CALERIE Study: design and methods of an innovative 25% caloric restriction
555	intervention. Contemp Clin Trials. 2011;32(6):874-81.
	11 Cabill CE. In Eval match aligns in stamation. Annual Bassiew of Nutwitian 2006;26:1
556	11. Cahill GF, Jr. Fuel metabolism in starvation. Annual Review of Nutrition. 2006;26:1-
557	22.
558	12. Newman JC, Verdin E. beta-Hydroxybutyrate: A Signaling Metabolite. Annual
559	review of nutrition. 2017;37:51-76.
560	13. Roberts MN, Wallace MA, Tomilov AA, Zhou Z, Marcotte GR, Tran D, et al. A
561	Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. Cell Metabolism.
562	2017;26(3):539-46.e5.

14. Newman JC, Covarrubias AJ, Zhao M, Yu X, Gut P, Ng C-P, et al. Ketogenic Diet
Reduces Midlife Mortality and Improves Memory in Aging Mice. Cell metabolism.
2017;26(3):547-57.e8.

15. Crabtree CD, Blade T, Hyde PN, Buga A, Kackley ML, Sapper TN, et al. Bis
 Hexanoyl (R)-1,3-Butanediol, a Novel Ketogenic Ester, Acutely Increases Circulating r- and
 s-ss-Hydroxybutyrate Concentrations in Healthy Adults. J Am Nutr Assoc. 2022:1-9.

569 16. Stubbs BJ, Cook C, Blonquist TM, Taggart K, Beckman D, Kruger C, et al. A
 570 randomized, open-label, cross-over pilot study investigating metabolic product kinetics of the
 571 palatable novel ketone ester, bis-octanoyl (R)-1,3-butanediol, and bis-hexanoyl (R)-1,3 572 butanediol ingestion in healthy adults. Toxicology Research. 2023 (submitted).

573 17. Stubbs BJ, Blade T, Mills S, Thomas J, Yufei X, Nelson FR, et al. In vitro stability
574 and in vivo pharmacokinetics of the novel ketogenic ester, bis hexanoyl (R)-1,3-butanediol.
575 Food Chem Toxicol. 2021;147:111859.

Koutnik AP, Poff AM, Ward NP, DeBlasi JM, Soliven MA, Romero MA, et al.
Ketone Bodies Attenuate Wasting in Models of Atrophy. J Cachexia Sarcopenia Muscle.
2020.

579 19. Koutnik AP, D'Agostino DP, Egan B. Anticatabolic Effects of Ketone Bodies in
580 Skeletal Muscle. Trends Endocrinol Metab. 2019;30(4):227-9.

Yurista SR, Matsuura TR, Sillje HHW, Nijholt KT, McDaid KS, Shewale SV, et al.
 Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in
 Preclinical Models of Heart Failure. Circ Heart Fail. 2021;14(1):e007684.

Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al.
 The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight.
 2019;4(4).

Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, et al. Ketogenic
Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. Cell.
2020;181(6):1263-75.e16.

Goldberg EL, Molony RD, Kudo E, Sidorov S, Kong Y, Dixit VD, et al. Ketogenic
 diet activates protective γδ T cell responses against influenza virus infection. Sci Immunol.
 2019;4(41).

593 24. Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of Exogenous Ketone
594 Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis. Adv Nutr.
595 2022.

Greaves G, Xiang R, Rafiei H, Malas A, Little JP. Prior ingestion of a ketone
 monoester supplement reduces postprandial glycemic responses in young healthy-weight
 individuals. Appl Physiol Nutr Metab. 2021;46(4):309-17.

Myette-Côté É, Caldwell HG, Ainslie PN, Clarke K, Little JP. A ketone monoester
drink reduces the glycemic response to an oral glucose challenge in individuals with obesity:
a randomized trial. The American Journal of Clinical Nutrition. 2019;110(6):1491-501.

Myette-Cote E, Neudorf H, Rafiei H, Clarke K, Little JP. Prior ingestion of
 exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance
 test in healthy young individuals. J Physiol. 2018;596(8):1385-95.

Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, et al. Nutritional Ketosis
 Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metabolism.
 2016;24:1-13.

Poffe C, Ramaekers M, Bogaerts S, Hespel P. Bicarbonate Unlocks the Ergogenic
Action of Ketone Monoester Intake in Endurance Exercise. Med Sci Sports Exerc.
2021;53(2):431-41.

30. Poffe C, Ramaekers M, Van Thienen R, Hespel P. Ketone ester supplementation
 blunts overreaching symptoms during endurance training overload. J Physiol.
 2019;597(12):3009-27.

Coleman K, Phillips J, Sciarini M, Stubbs B, Jackson O, Kernagis D. A Metabolic
 Intervention for Improving Human Cognitive Performance During Hypoxia. Aerospace
 medicine and human performance. 2021;92(7):556-62.

⁶¹⁷ 32. Evans M, Egan B. Intermittent Running and Cognitive Performance after Ketone
⁶¹⁸ Ester Ingestion. Med Sci Sports Exerc. 2018;50(11):2330-8.

33. Walsh JJ, Caldwell HG, Neudorf H, Ainslie PN, Little JP. Short-term ketone
 monoester supplementation improves cerebral blood flow and cognition in obesity: A
 randomized cross-over trial. J Physiol. 2021;599(21):4763-78.

A. Neudorf H, Myette-Côté É, P. Little J. The Impact of Acute Ingestion of a Ketone
 Monoester Drink on LPS-Stimulated NLRP3 Activation in Humans with Obesity. Nutrients.
 2020;12(3).

Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, et al. Acute
Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. J
Am Soc Echocardiogr. 2022;35(3):305-11.

628 36. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al.
 629 SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med.
 630 2013;158(3):200-7.

Gordon EH, Peel NM, Samanta M, Theou O, Howlett SE, Hubbard RE. Sex
 differences in frailty: A systematic review and meta-analysis. Exp Gerontol. 2017;89:30-40.

Mah E, Blonquist TM, Kaden VN, Beckman D, Boileau AC, Anthony JC, et al. A
 randomized, open-label, parallel pilot study investigating metabolic product kinetics of the
 novel ketone ester, bis-hexanoyl (R)-1,3-butanediol, over one week of ingestion in healthy
 adults. Front Physiol. 2023;14.

⁶³⁷ 39. Nieman KM, Anthony JC, Stubbs BJ. A Novel Powder Formulation of the Ketone
⁶³⁸ Ester, Bis Hexanoyl (R)-1,3-Butanediol, Rapidly Increases Circulating ss-Hydroxybutyrate
⁶³⁹ Concentrations in Healthy Adults. J Am Nutr Assoc. 2022:1-8.

40. Chen O, Blonquist TM, Mah E, Sanoshy K, Beckman D, Nieman KM, et al.
Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A
Randomized Controlled Trial in Healthy Adults. Nutrients. 2021;13(6).

41. Boler BM, Serao MC, Bauer LL, Staeger MA, Boileau TW, Swanson KS, et al.
Digestive physiological outcomes related to polydextrose and soluble maize fibre
consumption by healthy adult men. Br J Nutr. 2011;106(12):1864-71.

42. Maki KC, Rains TM, Kelley KM, Cook CM, Schild AL, Gietl E. Fibermalt is well
tolerated in healthy men and women at intakes up to 60 g/d: a randomized, double-blind,
crossover trial. Int J Food Sci Nutr. 2013;64(3):274-81.

43. Han MA, Tinetti ME, Agostini JV, Han L, Lee H, Walke LM. The impact of
medication use on symptom burden in older patients with multiple medical morbidities.
Journal of Clinical Gerontology and Geriatrics. 2013;4(3):84-8.

Chaudhry SI, Murphy TE, Gahbauer E, Sussman LS, Allore HG, Gill TM. Restricting
symptoms in the last year of life: a prospective cohort study. JAMA Intern Med.
2013;173(16):1534-40.

45. Nielsen R, Moller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al.
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic
Heart Failure Patients. Circulation. 2019;139(18):2129-41.

46. Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. On the Metabolism
 of Exogenous Ketones in Humans. Front Physiol. 2017;8:848.

47. Dearlove DJ, Faull OK, Rolls E, Clarke K, Cox PJ. Nutritional Ketoacidosis During
 Incremental Exercise in Healthy Athletes. Front Physiol. 2019;10:290.

48. Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N,
et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake
and Increases Blood Flow in Humans: A Positron Emission Tomography Study. J Am Heart
Assoc. 2017;6(3):e005066.

49. Svart M, Gormsen LC, Hansen J, Zeidler D, Gejl M, Vang K, et al. Regional cerebral
 effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake,

unchanged oxygen consumption and increased blood flow by positron emission tomography.
 A randomized, controlled trial. PLoS One. 2018;13(2):e0190556.

50. Soto-Mota A, Vansant H, Evans RD, Clarke K. Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults. Regul Toxicol Pharmacol. 2019;109:104506.

51. Soto□Mota A, Norwitz NG, Evans R, Clarke K, Barber TM. Exogenous ketosis in
patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control.
Endocrinology, Diabetes & Metabolism. 2021.

52. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21(4):418-24.

53. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med.
2002;166(1):111-7.

54. Pahor M, Kritchevsky SB, Waters DL, Villareal DT, Morley J, Hare JM, et al.
Designing Drug Trials for Frailty: ICFSR Task Force 2018. J Frailty Aging. 2018;7(3):150-4.

55. Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, et al.
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized,
Double-Blind, Placebo-Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci.
2017;72(11):1513-22.

56. Manini TM, Anton SD, Beavers DP, Cauley JA, Espeland MA, Fielding RA, et al.
 ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study: Concept, Rationale,
 and Design. Journal of the American Geriatrics Society. 2017;65(9):1961-8.

57. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect
of structured physical activity on prevention of major mobility disability in older adults: the
LIFE study randomized clinical trial. Jama. 2014;311(23):2387-96.

58. Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al.
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot
study. EBioMedicine. 2019;40:554-63.

59. Justice JN, Niedernhofer L, Robbins PD, Aroda VR, Espeland MA, Kritchevsky SB,
et al. Development of Clinical Trials to Extend Healthy Lifespan. Cardiovasc Endocrinol
Metab. 2018;7(4):80-3.

698 60. Perera S, Patel KV, Rosano C, Rubin SM, Satterfield S, Harris T, et al. Gait Speed
699 Predicts Incident Disability: A Pooled Analysis. The Journals of Gerontology: Series A.
700 2016;71(1):63-71.

Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R, Arnold A, et al. The
6-min walk test: a quick measure of functional status in elderly adults. Chest.
2003;123(2):387-98.

⁷⁰⁴ 62. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et
⁷⁰⁵ al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive
⁷⁰⁶ impairment. J Am Geriatr Soc. 2005;53(4):695-9.

Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain
Damage. Perceptual and Motor Skills. 1958;8(3):271-6.

64. Swindell WR, Cummings SR, Sanders JL, Caserotti P, Rosano C, Satterfield S, et al.
Data mining identifies Digit Symbol Substitution Test score and serum cystatin C as
dominant predictors of mortality in older men and women. Rejuvenation Res.
2012;15(4):405-13.

65. Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3
of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set
(UDS). Alzheimer Dis Assoc Disord. 2018;32(1):10-7.

66. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among
 community-living older persons. Arch Intern Med. 2006;166(4):418-23.

718 67. Walters SJ, Brazier JE. What is the relationship between the minimally important
719 difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes.
720 2003;1:4.

68. Curran S, Andrykowski M, Studts J. Short Form of the Profile of Mood States
(POMS-SF): Psychometric information... Psychol Assess. 1995;7:80-3.

Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep
quality index: A new instrument for psychiatric practice and research. Psychiatry Res.
1989;28(2):193-213.

726 70. Glynn NW, Santanasto AJ, Simonsick EM, Boudreau RM, Beach SR, Schulz R, et al.
727 The Pittsburgh Fatigability scale for older adults: development and validation. J Am Geriatr
728 Soc. 2015;63(1):130-5.

729 71. Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS). Clin Gerontol. 2008;5(1730 2):165-73.

731 72. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, et al. A
 732 framework for selection of blood-based biomarkers for geroscience-guided clinical trials:
 733 report from the TAME Biomarkers Workgroup. Geroscience. 2018;40(5-6):419-36.

734 73. Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, et al.
735 Association of inflammatory mediators with frailty status in older adults: results from a
736 systematic review and meta-analysis. Geroscience. 2020;42(6):1451-73.

737 74. Kane AE, Sinclair DA. Frailty biomarkers in humans and rodents: Current approaches
738 and future advances. Mech Ageing Dev. 2019;180:117-28.

739 75. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging.
740 2014;9:433-41.

741 76. Belsky DW, Huffman KM, Pieper CF, Shalev I, Kraus WE. Change in the Rate of
742 Biological Aging in Response to Caloric Restriction: CALERIE Biobank Analysis. J
743 Gerontol A Biol Sci Med Sci. 2017;73(1):4-10.

744 77. Howlett SE, Rockwood MR, Mitnitski A, Rockwood K. Standard laboratory tests to
 r45 identify older adults at increased risk of death. BMC Med. 2014;12:171.

746 78. Rockwood K, McMillan M, Mitnitski A, Howlett SE. A Frailty Index Based on
747 Common Laboratory Tests in Comparison With a Clinical Frailty Index for Older Adults in
748 Long-Term Care Facilities. J Am Med Dir Assoc. 2015;16(10):842-7.

749 79. NCI. Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool
 750 [Available from: <u>https://epi.grants.cancer.gov/asa24/</u>.

80. Newman JC, Sokoloski JL, Robbins PD, Niedernhofer LJ, Reed MJ, Wei J, et al.
Creating the Next Generation of Translational Geroscientists. J Am Geriatr Soc.
2019;67(9):1934-9.

Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, et al. A
ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT.
Alzheimer's & dementia : the journal of the Alzheimer's Association. 2021;17(3):543-52.

Visit Name	Phone Screen	Screening/ Consent Visit (1)	Acute Ketone Kinetics Visit (2)	Baseline Visit (3)	At Home	At Home	Interim Visit (4)	Phone Check In	Final Visit (5)
Time		Day -56 to -21	Day -42 to -7	Day 0	Days 1 to 14	Days 15 to 84	Week 4	Weeks 2, 6, 8 and 10	Week 12
SCREENING									-
Demographics	Х	Х							
Inclusion/Exclusion	Х	Х	Х	Х			Х	Х	Х
Interview for Frailty Measures	x	Х							х
Informed Consent		Х							
Review Medical History & Medication History		Х		Х			Х	Х	Х
Vitals/Anthropometrics		Х		Х			Х		Х
Blood and urine sampling – safety labs		Х		Х			Х		Х
Randomization		Х							
INTERVENTIONS									
Acute ketone kinetics			Х						
Daily study product consumption					x	x			
ASSESSMENTS			1		1	1	1	1	1
Capillary Blood Sampling			Х						
Assess tolerability			Х		X	Х	Х	X	X
Stool sample collection			Х	Х	X		Х		X
Blood and urine archiving – biomarker analysis				Х			Х		Х

X					Х
X					Х
X					X
X					X
	X	X			
	X				
			X	X	X
	X X	X X X X X X X X X X X	X X X X X X X X X X X X X X	X I X I X I X I X I X I X I X I X I X I X I X I X I X I X I X I X I	X Image: Constraint of the second s

 Figure 1: Schedule of BIKE Study screening, interventions and assessments- SPIRIT Figure

